Vai al contenuto principale
xMedica

NCT07784270ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Fase 31500 partecipanti ricercati230 centri16 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 218 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.

How this score is built
  • Enrolment32/40

    1,500 participants (target)

  • Site count25/25

    218 sites

  • Country count15/15

    16 countries

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomized, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM) and obesity or overweight. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Patologie

  • Obesity or Overweight
  • Diabetes Mellitus, Type 2

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥27 kg/m2 * Diagnosed with T2DM ≥90 days prior to Screening * HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling) * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 X ULN * AST ≥ 3.0 X ULN * TBL \> 1.5 X ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation * Use of insulin therapy for T2DM within 3 months prior to screening

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento1500 partecipanti ricercati

Sponsor e collaboratori

  • AstraZeneca Sponsor

Bracci e interventi

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventi

  • Farmaco Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Farmaco Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Esiti misurati

  1. Esito primario

    Percent change in body weight from baseline at 68 weeks of treatment.

    To evaluate the effect of AZD6234 compared to placebo in percent body weight change

    Orizzonte temporale 68 weeks

  2. Esito secondario

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on absolute change in weight

    Orizzonte temporale 68 weeks

  3. Esito secondario

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%

    Orizzonte temporale 68 weeks

  4. Esito secondario

    Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%

    Orizzonte temporale 68 weeks

  5. Esito secondario

    Change in haemoglobin A1C from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 on haemoglobin A1C change

    Orizzonte temporale 68 weeks

  6. Esito secondario

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on waist circumference change

    Orizzonte temporale 68 weeks

  7. Esito secondario

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change

    Orizzonte temporale 68 weeks

  8. Esito secondario

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change

    Orizzonte temporale 68 weeks

  9. Esito secondario

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants

    Orizzonte temporale 68 weeks

Date

Date
Data di inizio20 agosto 2026 (effettiva)
Conclusione primaria9 agosto 2028 (stimata)
Conclusione9 agosto 2028 (stimata)
Prima pubblicazione25 agosto 2026 (effettiva)
Ultimo aggiornamento28 ottobre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaottobre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

58 centri stanno reclutando

Argentina

Argentina
StrutturaCittàStato o regioneStato
Research SiteBuenos AiresIn reclutamento
Research SiteCABAIn reclutamento
Research SiteCiudad de Buenos AiresIn reclutamento
Research SiteMendozaIn reclutamento
Research SiteRamos MejíaNon ancora in reclutamento
Research SiteRosarioIn reclutamento
Research SiteSan NicolásNon ancora in reclutamento

Australia

Australia
StrutturaCittàStato o regioneStato
Research SiteBotanyIn reclutamento
Research SiteCamberwellIn reclutamento
Research SiteCharlestownIn reclutamento
Research SiteHelensvaleIn reclutamento
Research SiteMaroubraIn reclutamento
Research SiteWaitaraIn reclutamento

Canada

Canada
StrutturaCittàStato o regioneStato
Research SiteCalgaryAlbertaIn reclutamento
Research SiteHamiltonOntarioIn reclutamento
Research SiteJolietteQuebecIn reclutamento
Research SiteMarkhamOntarioIn reclutamento
Research SiteMonctonNew BrunswickIn reclutamento
Research SiteMontrealQuebecIn reclutamento
Research SiteMontrealQuebecIn reclutamento
Research SiteNorth YorkOntarioIn reclutamento
Research SiteQuébecQuebecIn reclutamento
Research SiteSarniaOntarioIn reclutamento
Research SiteScarborough VillageOntarioIn reclutamento
Research SiteStoney CreekOntarioRitirato
Research SiteStouffvilleOntarioIn reclutamento
Research SiteTorontoOntarioIn reclutamento
Research SiteTorontoOntarioIn reclutamento
Research SiteTrois-RivièresQuebecIn reclutamento
Research SiteTruroNova ScotiaIn reclutamento
Research SiteVancouverBritish ColumbiaIn reclutamento

Chile

Chile
StrutturaCittàStato o regioneStato
Research SiteConcepciónNon ancora in reclutamento
Research SiteConcepciónNon ancora in reclutamento
Research SiteConcepciónNon ancora in reclutamento
Research SiteIquiqueNon ancora in reclutamento
Research SiteLas CondesNon ancora in reclutamento
Research SiteProvidenciaNon ancora in reclutamento
Research SiteSantiagoNon ancora in reclutamento
Research SiteSantiagoNon ancora in reclutamento
Research SiteSantiagoNon ancora in reclutamento

China

China
StrutturaCittàStato o regioneStato
Research SiteBeijingNon ancora in reclutamento
Research SiteCangzhouNon ancora in reclutamento
Research SiteChangchunNon ancora in reclutamento
Research SiteChengduNon ancora in reclutamento
Research SiteChengduNon ancora in reclutamento
Research SiteDanyangNon ancora in reclutamento
Research SiteGanzhouNon ancora in reclutamento
Research SiteGuangzhouNon ancora in reclutamento
Research SiteHuizhouNon ancora in reclutamento
Research SiteHuzhouNon ancora in reclutamento

Nella scheda del registro sono indicati altri 180 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 28 ottobre 2026

    Data di conclusione posticipata

    Primary completion delayed 1 days

    2028-08-082028-08-09

  2. 28 ottobre 2026

    Centro aggiunto

    3 sites added (230 total)

    227230

  3. 22 settembre 2026

    Stato modificato

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  4. 22 settembre 2026

    Reclutamento aperto

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  5. 22 settembre 2026

    Data di conclusione anticipata

    Primary completion advanced 1 days

    2028-08-092028-08-08

  6. 22 settembre 2026

    Centro aggiunto

    9 sites added (227 total)

    218227